Now that Tilray stock is trading above $1 on speculation that President Trump will reclassify marijuana as a Schedule III drug (see Wednesday's issue), co has submitted an application requesting an extension to regain compliance with Nasdaq listing standards, it announced in press release. Tilray received a deficiency notice...
Read more...
Tilray Requests Nasdaq Extension to Regain Compliance Following Trump Bump
Publishing Info
- Year: 2025
- Volume: 27
- Issue #: 169
- Issue Date: 08/15/2025
Newsletter
INSIGHTS Express